Amphastar Pharmaceuticals’ (AMPH) Neutral Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their neutral rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research report released on Monday morning, Marketbeat.com reports. JPMorgan Chase & Co. currently has a $30.00 price target on the stock, down from their prior price target of $45.00.

AMPH has been the subject of several other reports. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Finally, Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $32.33.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $23.30 on Monday. The stock has a market cap of $1.11 billion, a P/E ratio of 7.77, a PEG ratio of 2.19 and a beta of 0.78. The stock has a 50 day simple moving average of $25.56 and a 200 day simple moving average of $34.33. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals has a 1-year low of $22.64 and a 1-year high of $53.96.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at $2,681,377.02. The trade was a 4.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have sold 5,231 shares of company stock worth $142,752. Insiders own 27.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. boosted its holdings in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after acquiring an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Boston Partners bought a new stake in Amphastar Pharmaceuticals during the fourth quarter worth $15,778,000. TD Asset Management Inc lifted its holdings in Amphastar Pharmaceuticals by 20.2% during the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock worth $64,130,000 after acquiring an additional 371,856 shares during the period. Finally, Wealthfront Advisers LLC bought a new stake in Amphastar Pharmaceuticals during the fourth quarter worth $9,268,000. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.